share_log

Tharimmune | 10-K: Annual report

Tharimmune | 10-K:年度報表

美股sec公告 ·  02/23 21:34
牛牛AI助理已提取核心訊息
Tharimmune, Inc., a clinical-stage biotechnology company, reported financial results for the fiscal year ended December 31, 2023. The company incurred a net loss of $9.3 million, compared to $8.5 million in the previous year. Research and development expenses increased by 56.2% to $3.6 million, primarily due to increased pre-clinical activities and licensing fees. General and administrative expenses also rose by 28.1% to $5.9 million, attributed to higher investor relations and personnel expenses. The company did not generate any revenue during the year. Tharimmune received FDA approval for an IND application for TH104, a product candidate for treating chronic pruritis in PBC patients. The company also advanced its early-stage pipeline, focusing on novel therapeutic candidates targeting immuno-oncology targets such as HER2, HER3, and PD-1. Tharimmune raised approximately $13.6 million...Show More
Tharimmune, Inc., a clinical-stage biotechnology company, reported financial results for the fiscal year ended December 31, 2023. The company incurred a net loss of $9.3 million, compared to $8.5 million in the previous year. Research and development expenses increased by 56.2% to $3.6 million, primarily due to increased pre-clinical activities and licensing fees. General and administrative expenses also rose by 28.1% to $5.9 million, attributed to higher investor relations and personnel expenses. The company did not generate any revenue during the year. Tharimmune received FDA approval for an IND application for TH104, a product candidate for treating chronic pruritis in PBC patients. The company also advanced its early-stage pipeline, focusing on novel therapeutic candidates targeting immuno-oncology targets such as HER2, HER3, and PD-1. Tharimmune raised approximately $13.6 million through public offerings of common stock, which contributed to a net increase in cash of $4.4 million for the year. The company's financial position includes cash and cash equivalents of $10.9 million as of December 31, 2023. Tharimmune's future plans involve continuing the development and potential commercialization of its product candidates, with an emphasis on addressing high unmet medical needs in rare diseases, inflammatory conditions, and cancer.
處於臨床階段的生物技術公司Tharimmune, Inc. 公佈了截至2023年12月31日的財年財務業績。該公司的淨虧損爲930萬美元,而去年同期爲850萬美元。研發費用增加了56.2%,達到360萬美元,這主要是由於臨床前活動和許可費的增加。一般和管理費用也增長了28.1%,至590萬美元,這要歸因於投資者關係和人事支出的增加。該公司在這一年中沒有產生任何收入。Tharimmune 獲美國食品藥品管理局批准 TH104 的臨床申請,該產品是治療PBC患者慢性瘙癢炎的候選產品。該公司還推進了其早期產品線,專注於針對HER2、HER3和PD-1等免疫腫瘤學靶標的新型候選療法。Tharimmun...展開全部
處於臨床階段的生物技術公司Tharimmune, Inc. 公佈了截至2023年12月31日的財年財務業績。該公司的淨虧損爲930萬美元,而去年同期爲850萬美元。研發費用增加了56.2%,達到360萬美元,這主要是由於臨床前活動和許可費的增加。一般和管理費用也增長了28.1%,至590萬美元,這要歸因於投資者關係和人事支出的增加。該公司在這一年中沒有產生任何收入。Tharimmune 獲美國食品藥品管理局批准 TH104 的臨床申請,該產品是治療PBC患者慢性瘙癢炎的候選產品。該公司還推進了其早期產品線,專注於針對HER2、HER3和PD-1等免疫腫瘤學靶標的新型候選療法。Tharimmune通過普通股的公開發行籌集了約1,360萬美元,這使該年度的現金淨增加440萬美元。截至2023年12月31日,該公司的財務狀況包括1,090萬美元的現金和現金等價物。Tharimmune的未來計劃包括繼續開發其候選產品並實現潛在的商業化,重點是解決罕見疾病、炎症和癌症中大量未得到滿足的醫療需求。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。